Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer

Despite initial promise, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based approaches to cancer treatment have yet to yield a clinically approved therapy, due to delivery challenges, a lack of potency, and drug resistance. To address these challenges, we have developed poly(beta-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaughan, Hannah J., Zamboni, Camila G., Radant, Nicholas P., Bhardwaj, Pranshu, Revai Lechtich, Esther, Hassan, Laboni F., Shah, Khalid, Green, Jordan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208964/
https://www.ncbi.nlm.nih.gov/pubmed/34189258
http://dx.doi.org/10.1016/j.omto.2021.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208964/
https://www.ncbi.nlm.nih.gov/pubmed/34189258
http://dx.doi.org/10.1016/j.omto.2021.04.004

Ejemplares similares